Ocular surface inflammation plays a pivotal role in dry eye and possibly in blepharitis. We hypothesize that the quantity of pro-inflammatory cytokines in tears and the expression of markers of inflammation on conjunctival cells are increased in…
ID
Bron
Aandoening
Blepharitis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Evaluation of HLA-DR expression levels after treatment with Azyter.
Achtergrond van het onderzoek
Blepharitis is a disease of the ocular surface which affects a growing number of patients, and to date there are no definitive treatments available. Inflammation plays a pivotal role in dry eye and possibly in blepharitis. Therefore, we hypothesize that the use of an antibiotic with anti-inflammatory activity may improve symptoms and signs of blepharitis and to reduce the level of ocular surface inflammation mesured as expression of inflammatory cell markers and quantity of inflammatory cytokines in tears.
Doel van het onderzoek
Ocular surface inflammation plays a pivotal role in dry eye and possibly in blepharitis. We hypothesize that the quantity of pro-inflammatory cytokines in tears and the expression of markers of inflammation on conjunctival cells are increased in patients with blepharitis. Furthermore, the aim of our project is to evaluate the effect of topical treatment with Azithromycin on symptoms, clinical signs, and ocular surface inflammation induced by blepharitis.
Onderzoeksopzet
7 and 21 days.
Onderzoeksproduct en/of interventie
Treatment with Azyter 2 times/day for 3 days and once/day for 3 days will be given at the study group (N=15).
The control group (N=15) includes patients with symptoms and signs of blepharitis as the treated group, but they will undergo the saline solution with the same posology.
Publiek
Stefano Barabino
Geneva 16132
Italy
+39 010 35338294
barabino@schepens.harvard.edu
Wetenschappelijk
Stefano Barabino
Geneva 16132
Italy
+39 010 35338294
barabino@schepens.harvard.edu
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Symptoms of blepharitis;
2. HLA-DR > 15% on conjunctival cells;
3. BUT <10 sec;
4. lid margin hyperemia >=2;
5. Meibum quality >= 10.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Glaucoma;
2. Ocular surface infections;
3. Corneal ulcer;
4. Conjunctival infections;
5. Treatment with anti-inflammatory drugs and cyclosporine in the 3 months preceding the study;
6. Surgical procedures in the 3 months preceding the study;
7. Antiglaucoma therapies;
8. Contact lens use 7 days before the study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3044 |
| NTR-old | NTR3192 |
| Ander register | METC : 9/2011 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
Samenvatting resultaten
Clin Exp Optom. 2011 Mar;94(2):200-6.